Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
Status:
RECRUITING
Trial end date:
2026-11-09
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Eculizumab in Chinese Adults with Neuromyelitis Optica Spectrum Disorders (NMOSD).